FDA Approves Avastin Plus Chemotherapy to Treat Women With Platinum-Resistant Recurrent Ovarian Cancer

November 14, 2014, the Food and Drug Administration announced the approval of Genentech’s Avastin (bevacizumab) in combination with chemotherapy for women with platinum-resistant recurrent ovarian cancer.

The approval was based on the results of a Phase III clinical trial which showed women who received Avastin with chemotherapy had a 62% improvement in progression free survival (disease worsening) as compared to those who received chemotherapy alone.